MEDICAL SCIENCES Correction for “Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors,” by Geoffrey Wayne Krampitz, Benson M. George, Stephen B. Willingham, Jens-Peter Volkmer, Kipp Weiskopf, Nadine Jahchan, Aaron M. Newman, Debashis Sahoo, Allison J. Zemek, Rebecca L. Yanovsky, Julia K. Nguyen, Peter J. Schnorr, Pawel K. Mazur, Julien Sage, Teri A. Longacre, Brendan C. Visser, George A. Poultsides, Jeffrey A. Norton, and Irving L. Weissman, which appeared in issue 16, April 19, 2016, of Proc Natl Acad Sci USA (113:4464–4469; first published March 31, 2016; 10.1073/pnas.1600007113).
The authors note that their conflict of interest statement was omitted during publication. The authors declare the following: “At the time of submission, I.L.W. and J.-P.V. were inventors on Stanford patents related to anti-CD47 reagents. At the time of publication, I.L.W. and J.-P.V. were cofounders and I.L.W. a Director of Forty Seven Inc., which licensed these patents and is developing therapeutics in the CD47 field. K.W. declares patents related to CD47-blocking therapies and equity and/or consulting relationships with Alexo Therapeutics and Forty Seven, Inc.”